1[1]M amounes E P, Wang J, Bryant J , et al. Patterns of loco - regional failure (LRF) in patients receiving neoadjuvant chemotherapy (NC): resul ts from NSABP B - 18 [J] Breast Cancer Research Treat, 2003, 82 (Supple 1): 17.
2[2]Cance W G, Carey L A, Calvo B F, et al. Long - term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservating and predicts outstanding local control and survival (J) Am Surg. 2002,236( 3 ):295.
3[3]Sanlglazov V F, Bojok A N Arsumamv A S, et al. Breast conserving surgery after neoadjuvant chanotherapy paclitaxel + doxorubicln vs fluorouracil + doxorubicin + cyclophosphanide in locally advanced breast cancer. [ J ] Breast Cancer Res Treat 2002, 76(Supple 1) :52.
4[4]Hetcheon, Ardrew W, Heys, et al. Neeadjuvant docetaxel in locally advanced breast cancer[ J] Breast Cancer Res Treat. 2003,79(Supple1) :19 -24
5[5]Amat S, Bougnoux P, Penault LlorcaF, etal. Neoadjuvant docetaxel for operable breast cancer induces a high pathological reslponse and breast- conservation rate, Br J Cancer, 2003 May 6,88 (9):1339 -45.
6[6]BraudAC, Levy E M Feuilhade F, et al. Canbinationof Vinarelbine, ePirubicirn and CyclophoSpamide as Neeadjuvant ( Chemtherapy for Locally Advanced Breast Cancer: Phase Ⅱ Study[ J] Am J Clin Onco, 2002, 25 (3) :303 -307.
7[7]Link J S, Forsthoff C A lbarra J, et al. Dose - dense doxorubicin docetaxel and cyclolphsphamide as sequential neoadjuvant therapy for high- risk breast cancer: a pilot study [J] Breast Cancer Reseach Treat. 2003, 82 (Supple 1) :59 -60.
8[8]DanfortH, David N Jr, Cowan, et al. Preoperative FLAC/Granulocyte - Colony - St imulat ing Factor Oaemotherapy for Stage ⅡBreast Cancer: A Prospective Randomized Trial[ J] Am Surg Onco,2003, 10(6) :635～644
9[9]Cheung Yun - Chung, (hen Shih - Oneh Su Min - Ying, et al.Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin)with serial enhaned MRI [J] Breast Cancer Research Treat. 2003,78(1) :51--58.
10[10]Balu- Maestro C, Chapellier C, Bleuse A, et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI [ J ]. Breast Cancer Res Treat, 2002,72 ( 2 ) 145 -152.
